CDK4/6 Inhibitors in Prostate Cancer: What CYCLONE 2 Tells Us About Abemaciclib + Abiraterone

Metastatic castration-resistant prostate cancer (mCRPC) remains one of the most challenging stages of prostate cancer to treat. Although several therapies can slow disease progression, resistance eventually develops. Researchers are continuously exploring combination strategies to improve outcomes.

One such effort was the phase 3 CYCLONE 2 trial, which tested whether adding the CDK4/6 inhibitor Abemaciclib to Abiraterone acetate could improve outcomes in men with mCRPC. 

The results, published in The Lancet Oncology, provide important lessons about combination therapy in prostate cancer.

This article explains the study in simple language — what was tested, what the results showed, and what it means for patients today.

What is mCRPC?

Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that:

• Has spread to other parts of the body (metastatic), and
• Continues to grow despite low testosterone levels achieved through hormone therapy (castration-resistant)

At this stage, cancer cells no longer respond fully to standard androgen deprivation therapy.

What Is Abiraterone?

Abiraterone is a medication that blocks the production of androgens (male hormones like testosterone) not only in the testes but also in the adrenal glands and tumor tissue. 

Since prostate cancer cells often depend on androgens to grow, blocking this pathway can slow disease progression.

Abiraterone is commonly given with prednisone or prednisolone to reduce side effects.

What Are CDK4/6 Inhibitors?

CDK4/6 inhibitors, including abemaciclib, are drugs that block proteins (CDK4 and CDK6) that help cancer cells divide and multiply. These drugs are widely used in hormone receptor–positive breast cancer.

Because CDK pathways may also play a role in prostate cancer growth, researchers wanted to test whether adding a CDK4/6 inhibitor to standard hormone therapy could improve results.

Why Combine Abemaciclib With Abiraterone?

The scientific idea behind CYCLONE 2 was simple:

• Abiraterone blocks androgen signaling.
• Abemaciclib blocks cell-cycle progression.
• Together, they might more effectively stop tumor growth.

Researchers hoped this dual inhibition would:

• Delay tumor progression on scans (radiographic progression-free survival or rPFS)
• Improve overall survival (OS)

CYCLONE 2 Trial Design

The CYCLONE 2 trial was a randomized, double-blind, phase 3 study conducted in 12 countries.

Who Participated?

A total of 393 men with mCRPC were enrolled between November 2018 and July 2022.

Key eligibility details:

• Patients could have previously received docetaxel for metastatic castration-sensitive disease.
• Patients could not have previously received abiraterone, apalutamide, enzalutamide, darolutamide, or any CDK4/6 inhibitor.

Treatment Groups

Participants were randomly assigned to one of two groups:

Group 1:

• Abiraterone (1,000 mg daily)
• Prednisone/prednisolone (5 mg twice daily)
• Abemaciclib (150–200 mg twice daily)

Group 2:

• Abiraterone (1,000 mg daily)
• Prednisone/prednisolone
• Placebo

The main goal (primary endpoint) was investigator-assessed radiographic progression-free survival (rPFS).

Key Results From CYCLONE 2

Primary Outcome: Radiographic Progression-Free Survival (rPFS)

After a median follow-up of about 26 months:

• rPFS events occurred in 45% of patients in the abemaciclib group
• rPFS events occurred in 51% of patients in the control group

Median rPFS:

• 22.0 months with abemaciclib
• 20.3 months with placebo

Hazard ratio (HR): 0.83
P value: 0.21

What Does This Mean?

Although the combination showed a small numerical improvement (about 1.7 months), the difference was not statistically significant. This suggests that the improvement could have occurred by chance and that the study did not meet its primary goal.

Overall Survival (OS)

Median overall survival:

• 38.0 months with abemaciclib
• 33.2 months with placebo

Hazard ratio: 0.93
P value: 0.65

There was no statistically significant survival benefit.

Secondary Endpoints

Some secondary outcomes showed differences:

• Time to PSA progression: 22.2 vs 16.6 months (HR 0.64, statistically significant)
• Time to symptomatic progression: 51.4 vs 35.7 months (not statistically significant)
• Time to worst pain progression: no meaningful difference

Although PSA progression improved, clinical practice is guided primarily by rPFS and overall survival. Since the main endpoint was not met, the trial is considered negative.

Safety and Side Effects

Side effects were more common in the abemaciclib group.

Grade 3 or Higher Adverse Events

• 68% in the abemaciclib group
• 51% in the control group

Most Common Serious Side Effects in the Abemaciclib Group

• Anemia (14%)
• Neutropenia (13%)
• Increased liver enzymes (9%)

Serious adverse events occurred in:

• 44% of patients in the abemaciclib group
• 37% in the control group

There were three treatment-related deaths in the abemaciclib group, all due to interstitial lung disease.

Overall, while safety was consistent with known effects of the drugs individually, toxicity was higher when abemaciclib was added.

CYCLONE 2 at a Glance

CYCLONE 2 in One Table: Treatment, Results, and Safety

Category	Abiraterone + Abemaciclib	Abiraterone Alone
Patients	206	187
Median rPFS	22.0 months	20.3 months
rPFS Result	Not statistically significant	—
Median Overall Survival	38.0 months	33.2 months
Time to PSA Progression	22.2 months	16.6 months
Grade 3+ Side Effects	68%	51%
Treatment-Related Deaths	3 (ILD)	0

What Does This Mean for Patients?

The key takeaway is clear:

Adding abemaciclib to abiraterone did not significantly improve radiographic progression-free survival in men with mCRPC.

Because the primary endpoint was not met, this combination is not considered a new standard of care for mCRPC.

Why Negative Trials Still Matter

Even though the study did not show a significant benefit, it provides valuable information:

• It prevents the use of ineffective combinations in large patient populations.
• It helps researchers better understand prostate cancer biology.
• It guides future research toward better-targeted strategies.

Sometimes, knowing what does not work is just as important as discovering what does.

What Comes Next?

Future research may focus on:

• Identifying biomarkers to select patients who may benefit from CDK4/6 inhibition
• Testing CDK4/6 inhibitors in different molecular subgroups
• Exploring new combinations beyond androgen pathway inhibition

Prostate cancer treatment continues to evolve, and researchers are working to find better strategies for patients with advanced disease.

Conclusion

The phase 3 CYCLONE 2 trial tested whether adding abemaciclib to abiraterone could improve outcomes in metastatic castration-resistant prostate cancer.

The study found no statistically significant improvement in radiographic progression-free survival or overall survival. Although some secondary measures, such as PSA progression, showed improvement, the primary goal was not achieved. Side effects were more frequent in the combination group.

For now, abiraterone remains a standard option in mCRPC, and CDK4/6 inhibitors like abemaciclib are not part of routine treatment for this disease outside clinical trials.

The results from CYCLONE 2 highlight the importance of carefully testing new combinations and continuing research to improve outcomes for men living with advanced prostate cancer.

References

1. The ASCO Post — Addition of Abemaciclib to Abiraterone in mCRPC (CYCLONE 2 news summary; posted Nov 3, 2025)
2. The Lancet Oncology  — Smith et al. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
3. PubMed — Record for the CYCLONE 2 phase 3 publication (Smith et al., 2025)
4. ClinicalTrials.gov — CYCLONE 2 trial registration (NCT03706365): Abiraterone + prednisone with or without abemaciclib in mCRPC